IBRX Q2 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+2423.9% YoY

Gross Profit

$26M99.5% margin

Operating Income

-$71M-269.8% margin

Net Income

-$93M-350.3% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+60.0%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$81M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$402M

Total Liabilities

$972M

Stockholders' Equity

-$571M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$1M	+2423.9%
Gross Profit	$26M	$1M	+2410.9%
Operating Income	-$71M	-$99M	+28.2%
Net Income	-$93M	-$135M	+31.2%

Revenue Segments

Product

$26M100%

Product and Service, Other

$4,0000%

Geographic Segments

UNITED STATES

$26M100%